Method for treating thrombosis and inhibiting platelet aggregation with 21-(S)-argatroban
    2.
    发明授权
    Method for treating thrombosis and inhibiting platelet aggregation with 21-(S)-argatroban 有权
    治疗血栓形成和抑制血小板聚集的方法,用21-(S) - 格列班班

    公开(公告)号:US08691844B2

    公开(公告)日:2014-04-08

    申请号:US13450443

    申请日:2012-04-18

    申请人: Honghai Song

    发明人: Honghai Song

    CPC分类号: A61K31/4709

    摘要: A method for inhibiting coagulation including administering to a patient in need thereof a pharmaceutical composition containing 21-(S)-Argatroban and/or a pharmaceutically acceptable salt thereof. Compared with 21-(R)-Argatroban, 21-(S)-Argatroban significantly prolongs coagulation time of whole blood (CT), recalcification time (RT), kaolin partial thromboplastin time (APTT), pro-time prothrombin time (PT), thrombin time (TT), and reduces platelet adhesion rate and platelet aggregation rate in healthy dogs. Therefore, 21-(S)-Argatroban has a stronger effect for inhibiting coagulation and reducing therapeutically effective dose and is suitable for use in a method for treatment and/or prevention of thrombosis and inhibiting platelet aggregation.

    摘要翻译: 一种抑制凝血的方法,包括向有需要的患者施用含有21-(S) - 阿格班班和/或其药学上可接受的盐的药物组合物。 与21-(R) - 阿格曲班相比,21-(S) - 阿格曲班显着延长了全血(CT)的凝血时间,再钙化时间(RT),高岭土部分凝血活酶时间(APTT),前期凝血酶原时间(PT) ,凝血酶时间(TT),降低健康犬血小板粘附率和血小板聚集率。 因此,21-(S) - 阿格曲班对抑制凝血和降低治疗有效剂量具有更强的作用,适用于治疗和/或预防血栓形成和抑制血小板聚集的方法。